Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Fractyl Health announced its Q4 and full year 2025 financial results alongside encouraging clinical updates. The company completed randomization in its REMAIN-1 Pivotal Cohort and expects topline 6-month data in early Q4 2026 for its Revita therapy, designed to maintain weight after discontinuation of GLP-1 drugs. Post-hoc analyses demonstrate a do…